Pharmaxis to raise further funds

By Renate Krelle
Tuesday, 02 November, 2004

Following its recent announcement of a successful Phase III trial of the successful completion of a Phase III clinical trial for its asthma diagnostic and treatment management tool Aridol, Sydney's Pharmaxis (ASX:PXS) has entered a trading halt -- to be lifted tomorrow morning -- pending the announcement of details of a placement and share purchase plan.

The company will conduct the placement via a bookbuild.

AusBiotech partners with Tenmile

Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...

Australian CDC issues update in wake of Ebola outbreak

After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...

Australia announces $7.2m diphtheria outbreak response package

To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...

Content from other channels on our network

From Dark Age to Imperial: what Age of Empires teaches us about instrumentation

WA Government to boost development of Collie green steel mill

Queensland increases investment in CopperString

Demystifying zero trust in OT

LION to close James Boag's Brewery in Launceston

Larry Emdur's whisky brand appoints CEO

Fonterra's leadership changes confirmed

Driving food safety through digital traceability and transparency

Mars expands local pet food production with new $112.6m facility now open

New analytical method for testing gluten-free beer assessed

Australian health care's burnout prescription

"Fake podiatrist" jailed after hundreds of consultations with vulnerable patients

Unlocking the potential of our nursing workforce

National Model for Clinical Governance now available

SEKO IoT solutions revolutionise on-premise laundry dosing